Addition of Gonadotropin Releasing Hormone Agonist to Luteal Phase Support

PHASE4CompletedINTERVENTIONAL
Enrollment

75

Participants

Timeline

Start Date

March 17, 2022

Primary Completion Date

October 27, 2023

Study Completion Date

January 18, 2024

Conditions
Female Infertility
Interventions
DRUG

gonadotropin releasing hormone-agonist

subcutaneous injection

DRUG

Progesterone

vaginal suppositories (400 mg twice daily) starting on the day after oocyte retrieval and will be continued till pregnancy assessed by serum β-HCG 15 days after ICSI, and if pregnant, for 10 weeks of gestation.

Trial Locations (1)

21526

Alexandria University, Alexandria

All Listed Sponsors
lead

Alexandria University

OTHER